

Original Article

In-hospital and late outcomes of patients undergoing percutaneous mitral valvuloplasty in a center with intermediate volume of structural procedures

Pedro Beraldo de Andrade^{a,*}, Marden André Tebet^b, Fábio Salerno Rinaldi^a, Igor Ribeiro de Castro Bienert^c, Luis Fernando Carvalho^c, João Antônio de Toledo Galina^c, Robson Alves Barbosa^a, Ederlon Ferreira Nogueira^d, Sérgio Kreimer^b, Vinícius Cardozo Esteves^b, Luiz Alberto Piva e Mattos^b, André Labrunie^a

^a Irmandade da Santa Casa de Misericórdia de Marília, Marília, SP, Brazil

^b Rede D'Or São Luiz, São Paulo, SP, Brazil

^c Hospital das Clínicas, Faculdade de Medicina de Marília, Marília, SP, Brazil

^d Hospital do Coração de Londrina, Londrina, PR, Brazil

ARTICLE INFO

Article history:

Received 14 May 2015

Accepted 17 June 2015

Keywords:

Mitral valve stenosis
Balloon valvuloplasty
Rheumatic fever

ABSTRACT

Background: Percutaneous mitral valvuloplasty is the treatment of choice for rheumatic mitral stenosis with favorable anatomy, for its ability to prevent complications inherent to a surgical procedure, while maintaining effectiveness. It is necessary to promote comparisons between the results obtained by the procedure performed at referral centers with high patient inflow and at institutions with lower volume and fewer patients, which represents the main objective of this study.

Methods: Thirty-one consecutive patients undergoing percutaneous mitral valvuloplasty were analyzed from September 2006 to January 2015. Immediate procedural success and late event-free survival rates were evaluated, defined as cardiovascular death or need for a new mitral valve intervention.

Results: The mean age was 40.9 ± 14.2 years, with a predominance of females (96.8%). The mean Wilkins and Block score was 8.1 ± 1.2 . All procedures were performed using the Inoue technique, with an immediate success rate of 90.3%. At mean follow-up of 6.8 ± 2.5 years, seven events (22.6%) were observed: two cardiovascular deaths, four surgeries for mitral valve replacement, and one mitral commissurotomy.

Conclusions: In a hospital with intermediate procedure volume, the results of percutaneous mitral valvuloplasty in the treatment of rheumatic mitral stenosis with favorable anatomy were comparable to those achieved by high-volume centers.

© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Desfechos hospitalares e tardios de pacientes submetidos à valvoplastia mitral percutânea em centro com volume intermediário de procedimentos estruturais

RESUMO

Introdução: A valvoplastia mitral percutânea é o tratamento de escolha da estenose mitral reumática com anatomia favorável, por sua capacidade de prevenir complicações inerentes ao tratamento cirúrgico e com manutenção da eficácia. Faz-se necessário promover comparações entre os resultados obtidos com o procedimento por centros de referência e alta drenagem de pacientes e por instituições de menor volume e casuística, sendo este o objetivo principal deste estudo.

Métodos: Foram analisados 31 pacientes consecutivos submetidos à valvoplastia mitral percutânea no período de setembro de 2006 a janeiro de 2015. Avaliaram-se o sucesso imediato do procedimento e a sobrevida livre de eventos tardios, definidos como morte cardiovascular ou necessidade de nova intervenção valvar mitral.

Resultados: A média de idade foi de $40,9 \pm 14,2$ anos, com predomínio do sexo feminino (96,8%). O escore médio de Wilkins e Block foi de $8,1 \pm 1,2$. A totalidade dos procedimentos foi efetivada pela técnica de Inoue, com taxa de sucesso imediato de 90,3%. Em acompanhamento médio de $6,8 \pm 2,5$ anos, foram constatados sete eventos (22,6%), sendo dois óbitos de etiologia cardiovascular, quatro cirurgias de troca valvar mitral e uma comissurotomia mitral.

Palavras-chave:

Estenose da valva mitral
Valvuloplastia com balão
Febre reumática

DOI of original article: <http://dx.doi.org/10.1016/j.rbc.2016.02.003>

* Corresponding author: Avenida Vicente Ferreira, 828, Jardim Maria Izabel, CEP: 17515-900, Marília, SP, Brazil.

E-mail: pedroberaldo@gmail.com (P.B. de Andrade).

Peer review under the responsibility of Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista.

Conclusões: Em um hospital com volume intermediário de procedimentos, os resultados da valvoplastia mitral percutânea no tratamento da estenose mitral reumática com anatomia favorável foram comparáveis àqueles alcançados por centros de alto referenciamento.

© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The prevalence of rheumatic fever, the predominant etiology of mitral stenosis, has undergone a significant reduction in Western countries, but percutaneous mitral valvuloplasty (PMV) is still the treatment of choice in patients with favorable valve anatomy, for its ability to prevent complications inherent to the surgical procedure, while maintaining effectiveness.¹⁻³ The procedure can be accomplished by different methods, such as the single balloon, double balloon, or metallic commissurotomy method, with the Inoue⁴ technique representing the most commonly used, as it is simpler to perform, has a shorter procedure duration, and has lower incidence of complications, with late evolution comparable to that of the others.⁵⁻⁷

In spite of the frequent need for reinterventions after a successful PMV, survival free of cardiovascular death, surgical valve replacement or NYHA class III or IV are approximately 50% in a follow-up period of up to 20 years in high-volume centers.^{8,9} It is necessary, however, to promote comparisons between the results obtained with the procedure as performed by referral centers with high patient inflow and by institutions with lower volume and fewer patients, which represents the main objective of this study.

Methods

Study population

The study population consisted of a cohort of 31 consecutive patients with moderate to severe mitral stenosis of rheumatic etiology (mitral valve area ≤ 1.5 cm²), clinically symptomatic (functional class > II), with favorable valve morphology, submitted to PMV at Santa Casa de Marília, in Marília (SP), Brazil, from September 2006 to January 2015.

Procedures

Under superficial sedation and local anesthesia, right femoral venous access was obtained with a 7 F femoral sheath, while left femoral arterial access was obtained with a 5 F femoral sheath. Pulmonary capillary, main pulmonary artery, right ventricle, right atrium, left ventricle, and aorta pressures were obtained retrogradely. Left ventriculography was performed in right anterior oblique projection at 30°, and the degree of mitral regurgitation was established according to Sellers' classification. In patients older than 40 years, the assessment was complemented with coronary angiography.

The Brockenbrough technique was used for the transseptal puncture, under continuous pressure monitoring and using a pigtail catheter positioned above the aortic valve as reference. After the transseptal puncture, a Mullins catheter was maintained in the left atrial cavity, and 2,500 IU of heparin were administered. After the mitral valve pressure gradient was recorded, the spiral guidewire was introduced up to the left atrium, followed by atrial septum dilation using a 14 F dilator. The Inoue balloon size was determined by the formula given by the equation:

$$\text{maximum balloon diameter (mm)} = [\text{patient's height (m)} \times 10] + 10$$

The balloon was advanced over the guidewire, with its distal extremity close to the mitral valve orifice. The balloon was then partially inflated with 1 to 2 mL of diluted contrast to facilitate its fluctuation through the valve orifice and prevent its passage through the chordae tendineae. With the help of a stylet, the balloon was directed in order to surpass the mitral valve. The distal portion of the balloon was inflated and the set was retracted up to its anchoring position at the ventricular face of the mitral valve. Then, the proximal portion of the balloon was inflated, resulting in an hourglass shape, until the medial constraint disappeared at full inflation. The pigtail catheter was advanced into the left ventricular cavity for analysis of residual mitral gradient. When available, two-dimensional transthoracic echocardiography was performed at this point. If the result was considered inadequate, the balloon was introduced again for additional inflations with larger volume. At the end of the procedure, manometry of the right chambers and the control left ventriculography were recorded. Echocardiography was routinely performed 24 to 48 hours after the PMV, with the mitral valve area being assessed by planimetry.

Definitions and outcomes of interest

Procedural success was defined by the increase in mitral valve area $\geq 25\%$ of the original area and final valve area ≥ 1.5 cm², in the absence of severe mitral regurgitation ($> 2/4$) and severe cardiac or cerebrovascular adverse events, such as death, stroke, cardiac tamponade, or mitral valve surgery. The outcomes assessed in the late follow-up were cardiovascular death and the need for a new percutaneous or surgical mitral valve intervention.

Statistical analysis

All data were prospectively stored in a registry started in 2006. The estimate of event-free survival was determined according to the Kaplan-Meier method. The qualitative variables were summarized as absolute frequencies and percentages. Quantitative data were expressed as means and standard deviations.

Results

Clinical and demographic characteristics of patients are shown in Table 1. The mean age was 40.9 ± 14.2 years, with a predominance of females (96.8%). The mean Wilkins and Block score was 8.1 ± 1.2 . Among the procedures, one was performed in a pregnant woman and five in patients with previous mitral commissurotomy. After 2007, there was stabilization in the mean volume of cases, with the performance of approximately four PMVs per year.

All of the procedures were carried out using the Inoue technique. The success rate was 90.3%, and the three unsuccessful procedures were attributed to transseptal puncture failure ($n = 2$) and cardiac tamponade ($n = 1$). Transthoracic echocardiography monitoring was used in 80.6% of cases. The characteristics of the echocardiographic procedures and information are shown in Table 2.

Table 1
Clinical and demographic characteristics of patients.

Variables	n = 31
Age, years	40.9 ± 14.2
Female gender, n (%)	30 (96.8)
Body mass index, kg/m ²	26.4 ± 6.0
Systemic arterial hypertension, n (%)	4 (12.9)
Diabetes mellitus, n (%)	2 (6.5)
Dyslipidemia, n (%)	3 (9.7)
Smoking, n (%)	4 (12.9)
Coronary atherosclerosis, n (%)	4 (12.9)
Previous stroke, n (%)	3 (9.7)
Atrial fibrillation, n (%)	3 (9.7)
Pregnant patient, n (%)	1 (3.2)
Previous mitral commissurotomy, n (%)	5 (16.1)
Previous mitral valvuloplasty, n (%)	0 (0.0)
Wilkins and Block valvular score	8.1 ± 1.2
Heart failure, n (%)	
Functional class II	10 (32.2)
Functional class III	18 (58.1)
Functional class IV	3 (9.7)
Year of the procedure, n	
2006	1
2007	8
2008	4
2010	5
2011	4
2012	4
2013	0
2014	4
2015	1


Table 2
Characteristics and outcomes of percutaneous mitral valvuloplasty.

Variable	n = 31
Inoue technique, n (%)	31 (100.0)
Access, n (%)	
Right femoral vein	29 (93.5)
Left femoral vein	2 (6.5)
Procedure duration, minutes	71.4 ± 21.7
Time of fluoroscopy, minutes	18.1 ± 9.5
Periprocedural transthoracic echocardiography, n (%)	25 (80.6)
Procedural success, n (%)	28 (90.3)
Mitral valve area, pre-valvuloplasty, cm ²	0.9 ± 0.2
Mitral valve area, post-valvuloplasty, cm ²	1.8 ± 0.3
Mean diastolic transvalvular gradient, pre-valvuloplasty, mmHg	16.8 ± 4.9
Mean diastolic transvalvular gradient, post-valvuloplasty, mmHg	3.9 ± 2.2
Mean pulmonary arterial pressure, pre-valvuloplasty, mmHg	37.7 ± 12.6
Mean pulmonary arterial pressure, post-valvuloplasty, mmHg	28.6 ± 9.2

Seven events (22.6%) were observed during a mean follow-up of 6.8 ± 2.5 years: two cardiovascular deaths, four mitral valve replacement surgeries, and one mitral commissurotomy. The estimate of event-free survival at 8 years by the Kaplan-Meier method was 72.5% (Fig. 1). In the subgroup of patients with previous mitral commissurotomy (16.1%), immediate success was obtained in all cases, and the late follow-up showed one case of restenosis with mitral valve replacement surgery.

Discussion

A pioneering modality in the non-surgical approach to acquired valvular disease, PMV is a complex procedure, associated with a learning curve, especially due to the need for transseptal puncture.

**Figure 1.** Estimate of cardiovascular death or new mitral valve procedure-free survival over 8 years.

Late outcomes of large series of patients have been recently published, demonstrating that it is a well-established technique that brings long-term benefits to patient prognosis.

Of the 1,024 patients undergoing PMV between the years 1986 and 1995 in France, the survival free of cardiovascular death or new surgical or percutaneous mitral valve intervention in 20 years was 30.2%.⁹ In mean follow-up of 11.6 years of 482 patients who underwent the procedure in an Italian registry, the event rate was 41.9%, mainly due to the need for mitral valve surgery (27%).¹⁰ In Brazil, very late outcomes involving up to 308 patients demonstrated lasting results, with restenosis-free survival over 20 years in more than one-third of the cases.^{11,12} Together, these data reflect the experience of major referral centers in structural interventions with high patient inflow.

The present series, although modest, shows a high success rate, and low complication and event-free survival rates, comparable to those in large centers.¹³ Some aspects may justify these findings. The main aspect is the selection of patients favorable to the used technique, such as non-advanced age, prevalence of sinus rhythm (90.3%), and mean echocardiographic score of 8.1 – factors that are known to be associated with better late outcomes.^{9,12,14} Speculatively, another strategy used on a recurring basis and that could help prevent complications was the periprocedural echocardiographic monitoring in 80.6% of cases. As the echocardiography in the intervention laboratory provides fast and accurate information of the mitral valve area and the degree of regurgitation, additional balloon inflations can be prevented and the subsequent establishment or worsening of valve regurgitation.

A subgroup of patients undergoing PMV of special interest are those with restenosis after surgical mitral commissurotomy, as percutaneous treatment, when feasible, prevents valve replacement and its consequent late implications. However, the previous commissurotomy is traditionally considered a variable that predicts worse immediate and late post-procedural outcomes.¹⁵ The present data were favorable in this population, in line with the most recent publications, which show immediate success in over 80% of cases and survival free of mitral surgery in 20 years in up to one-third of the patients.¹⁶

The main limitation of the study was the small sample size and the reproducibility of its findings. Despite the intermediate volume of procedures, the interventionists involved with these procedures directly participated, during their training, in approximately 30 PMV, thus meeting the learning curve. With the decrease in the prevalence of rheumatic mitral stenosis, acquiring proficiency in the stages of the procedure, such as transseptal puncture, becomes impaired. However, the advent of new imaging technologies and devices applicable in several types of structural and degenerative diseases, the left atrial appendage closure in patients with atrial fibrillation, and the therapeutic role in arrhythmias have the potential to rescue the puncture technique due to the common need to have antegrade access to the left atrium.

Conclusions

The results obtained with the Inoue technique in percutaneous mitral valvuloplasty in patients with rheumatic mitral stenosis in a tertiary hospital with an intermediate volume of structural procedures were comparable to those achieved by reference centers with high patient inflow.

Funding source

None declared.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Grube E, Sinning JM, Vahanian A. The year in cardiology 2013: valvular heart disease (focus on catheter-based interventions). *Eur Heart J*. 2014;35(8):490-4.
2. Tarasoutchi F, Montera MW, Grinberg M, Barbosa MR, Piñeiro DJ, Sánchez CR, et al. Brazilian Guidelines for Valve Disease - SBC 2011/I Guideline Inter-American Valve Disease - 2011 SIAC. *Arq Bras Cardiol*. 2011;97(5 Suppl. 1):1-67. Portuguese.
3. Bueno RR, Guérios EE, Andrade PM, Nercolini DC, Tarastchuk JC, Ultramari FT. Comparação dos resultados da valvoplastia mitral percutânea e cirúrgica em longo prazo. *Rev Bras Cardiol Invasiva*. 2005;13(2):112-5.
4. Inoue K, Owaki T, Nakamura T, Kitamura F, Miyamoto N. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. *J Thorac Cardiovasc Surg*. 1984;87(3):394-402.
5. Cardoso CO, Silva EO, Rodrigues Jr. LH, Torrano S, Cardoso CR, Haertel JC, et al. Valvotomia mitral percutânea: experiência inicial com o novo balão único de dilatação "tipo Inoue". *Rev Bras Cardiol Invasiva*. 2009;17(4):518-25.
6. Kang DH, Park SW, Song JK, Kim HS, Hong MK, Kim JJ, et al. Long-term clinical and echocardiographic outcome of percutaneous mitral valvuloplasty: randomized comparison of Inoue and double-balloon techniques. *J Am Coll Cardiol*. 2000;35(1):169-75.
7. Guérios EE, Bueno RR, Nercolini DC, Tarastchuk JC, Andrade PM, Pacheco AL, et al. Randomized comparison between Inoue balloon and metallic commissurotomy in the treatment of rheumatic mitral stenosis: immediate results and 6-month and 3-year follow-up. *Catheter Cardiovasc Interv*. 2005;64(3):301-11.
8. Bouleti C, lung B, Himbert D, Brochet E, Messika-Zeitoun D, Détaint D, et al. Reinterventions after percutaneous mitral commissurotomy during long-term follow-up, up to 20 years: the role of repeat percutaneous mitral commissurotomy. *Eur Heart J*. 2013;34(25):1923-9.
9. Bouleti C, lung B, Laouénan C, Himbert D, Brochet E, Messika-Zeitoun D, et al. Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients. *Circulation*. 2012;125(17):2119-27.
10. Tomai F, Gaspardone A, Versaci F, Ghini AS, Altamura L, De Luca L, et al. Twenty year follow-up after successful percutaneous balloon mitral valvuloplasty in a large contemporary series of patients with mitral stenosis. *Int J Cardiol*. 2014;177(3):881-5.
11. Peixoto EC, Borges IP, Peixoto RT, Oliveira PS, Netto MS, Labrunie P, et al. Evolução a longo prazo da valvoplastia mitral percutânea por balão: análise dos fatores de risco para óbito e eventos maiores e da evolução de grupo de risco. *Rev Bras Cardiol Invasiva*. 2005;13(2):69-76.
12. Aguiar Filho GB, Lluberias S, Gomes NL, Andrade LF, Maldonado M, Meneghelo ZM, et al. Evolução muito tardia da valvotomia percutânea por balão na estenose mitral grave. *Rev Bras Cardiol Invasiva*. 2012;20(3):253-9.
13. Lemos DC, Marin-Neto JA, Lima Filho MO, Figueiredo GL, Lago IM, Macedo LG. Valvoplastia mitral pela técnica de Inoue: registro do Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. *Rev Bras Cardiol Invasiva*. 2011;19(1):72-7.
14. Cardoso LF, Ayres CV, Bento AM, Tarasoutchi F, Vieira ML, Grinberg M. Immediate and late results of percutaneous mitral valve repair in patients with mitral stenosis. *Arq Bras Cardiol*. 2010;94(3):383-90.
15. Palacios IF, Sanchez PL, Harrell LC, Weyman AE, Block PC. Which patients benefit from percutaneous mitral balloon valvuloplasty? Prevalvuloplasty and postvalvuloplasty variables that predict long-term outcome. *Circulation*. 2002;105(12):1465-71.
16. Bouleti C, lung B, Himbert D, Brochet E, Messika-Zeitoun D, Détaint D, et al. Long-term efficacy of percutaneous mitral commissurotomy for restenosis after previous mitral commissurotomy. *Heart*. 2013;99(18):1336-41.